Qurient Co. Ltd (KQ:115180) — Market Cap & Net Worth
Market Cap & Net Worth: Qurient Co. Ltd (115180)
Qurient Co. Ltd (KQ:115180) has a market capitalization of $579.17 Million (₩854.63 Billion) as of June 19, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #11641 globally and #325 in its home market, demonstrating a -1.41% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Qurient Co. Ltd's stock price ₩24500.00 by its total outstanding shares 34882741 (34.88 Million). Review total liabilities of Qurient Co. Ltd to assess the company's total debt and financial obligations.
Qurient Co. Ltd Market Cap History: 2025 to 2026
Qurient Co. Ltd's market capitalization history from 2025 to 2026. Data shows growth from $715.10 Million to $579.17 Million (0.00% CAGR).
Index Memberships
Qurient Co. Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$270.08 Billion | 0.21% | #81 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$270.08 Billion | 0.21% | #81 of 1384 |
Weight: Qurient Co. Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Qurient Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Qurient Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 115180 by Market Capitalization
Companies near Qurient Co. Ltd in the global market cap rankings as of June 19, 2026.
Key companies related to Qurient Co. Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.20 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €762.80 |
Qurient Co. Ltd Historical Marketcap From 2025 to 2026
Between 2025 and today, Qurient Co. Ltd's market cap moved from $715.10 Million to $ 579.17 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩579.17 Million | -19.01% |
| 2025 | ₩715.10 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Qurient Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $579.17 Million USD |
| MoneyControl | $579.17 Million USD |
| MarketWatch | $579.17 Million USD |
| marketcap.company | $579.17 Million USD |
| Reuters | $579.17 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Qurient Co. Ltd
Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company's pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as … Read more